May 17 |
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
|
May 17 |
Dermata Therapeutics GAAP EPS of -$0.47 beats by $5.83
|
May 15 |
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
Apr 2 |
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
|
Mar 27 |
Dermata to Present at the Emerging Growth Conference on April 3, 2024
|
Mar 21 |
Dermata Therapeutics GAAP EPS of -$2.67 beats by $1.55
|
Mar 21 |
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
|
Feb 6 |
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
|
Feb 1 |
Dermata to Present at the Emerging Growth Conference on February 7, 2024
|
Jan 5 |
Dermata stock soars on patent issuance, partnership talks
|